Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOAC Interruption Schedule Before Atrial Fibrillation Ablation
NCT02504177Unknown
- Sponsor
- Yonsei University
- Start
- Jun 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dabigatran etexilate oral solution, rivaroxaban and apixaban in Atrial fibrillation (AFib) (2 arms), sponsored by Yonsei University. Primary endpoint: Incidence of major bleeding complications at 30 days. Status: unknown.
02
Drugs
dabigatran etexilate oral solutionrivaroxabanapixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02504177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504177.